DGAP-News: Evotec and Yale University to collaborate on cancer therapy
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): Alliance
Evotec and Yale University to collaborate on cancer therapy
17.12.2013 / 07:30
---------------------------------------------------------------------
* First collaboration within open innovation alliance with Yale University
* Collaborative effort will explore novel mechanisms, targets and
compounds that have the potential to interfere with DNA repair to identify
new targets for drug discovery and development
Hamburg, Germany - 17 December 2013: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) today announced a research collaboration,
TargetDBR (DNA Break Repair), with the laboratories of Prof. Peter Glazer
and Prof. Ranjit Bindra at Yale School of Medicine. The objective of this
collaboration is to identify novel mechanisms, targets and compounds that
have the potential to interfere with DNA repair. DNA repair mechanisms
allow cancer cells to cope with extensive genome rearrangements as well as
to escape conventional radio- and chemotherapy and thus have potential
applications in many cancer indications. This is the first collaboration to
be announced as part of Evotec's open innovation alliance with Yale
University.
TargetDBR is based on systematic cell screens designed to identify DNA
repair inhibitors and their mechanisms of action. The application of
Evotec's high-content cellular screening platforms allied to
chemoproteomics-based target deconvolution will enable the identification
not only of novel DNA repair inhibitors but also of novel tractable targets
in DNA repair pathways. The initial focus will be on increasing the
effectiveness of glioblastoma brain tumour treatments but it is expected
that the DNA repair inhibitors will also find application in many other
cancer types. Yale and Evotec will collaborate in a highly integrated
fashion and share potential commercial rewards.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented:
'Deficiencies in DNA repair mechanisms constitute not only initiating
events leading to cancer but also provide potential therapeutic targets on
the basis of the concept of synthetic lethality. We are very excited about
the opportunity to collaborate with Peter and Ranjit to identify and
develop novel classes of DNA repair inhibitors that have the potential to
become highly effective therapeutics against difficult to treat cancers
such as glioblastoma.'
'Through this collaboration with Evotec, novel biological discoveries and
medical insights made at Yale are being effectively translated into a
state-of-the-art drug discovery project. The collaboration is already
demonstrating the benefit of the Yale Evotec open innovation alliance in
accelerating drug discovery projects', said Dr Jon Soderstrom, Managing
Director of Yale's Office of Cooperative Research.
Financial details were not disclosed.
ABOUT THE EVOTEC AND YALE OPEN INNOVATION ALLIANCE
In January 2013, Evotec AG and Yale University entered into a strategic
partnership. Under the agreement, Evotec and Yale are leveraging first rate
science performed at Yale University together with Evotec's drug discovery
infrastructure and expertise into highly innovative discovery approaches in
diseases of high unmet medical need. Evotec and Yale have defined a wide
range of scientific fields including metabolic diseases, CNS, immunological
diseases and cancer where they will jointly assess and potentially pursue
novel assays, screens and models but in particular exploratory drug targets
and compounds. The intention is to seamlessly integrate Evotec's drug
discovery infrastructure with highly innovative biology at Yale to mature
individual projects to a stage where they can be commercialised.
ABOUT GLIOBLASTOMA
The most common primary malignant brain tumours are malignant gliomas and
glioblastomas. Whilst the incidence is relatively low at about 2-3 cases
per 100,000 people, glioblastoma tumours are aggressive resulting in a
dismal prognosis for patients and an associated poor quality of life.
Standard-of-care therapy involves radiation and chemotherapy with
temozolomide and provides a median survival of 15 months.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca
and Ono Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
www.evotec.com.
ABOUT YALE
Founded in 1810, the Yale School of Medicine is a world-renowned centre for
biomedical research, education and advanced health care. Among its 27
departments are one of the nation's oldest schools of public health and the
internationally recognized Child Study Center, founded in 1911. Yale School
of Medicine consistently ranks among the handful of leading recipients of
research funding from the National Institutes of Health and other
organizations supporting the biomedical sciences. Its core faculty of more
than 1,100 physicians and scientists is well represented within the
Institute of Medicine and National Academy of Sciences and among
investigators of the Howard Hughes Medical Institute. The Yale Center for
Molecular Discovery provides Yale researchers with access to drug discovery
expertise and support services.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen(at)evotec.com
End of Corporate News
---------------------------------------------------------------------
17.12.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
245053 17.12.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.12.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 324828
Anzahl Zeichen: 10495
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 592 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Evotec and Yale University to collaborate on cancer therapy"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
